English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduDr. Sanaz Memarzadeh has received two grants totaling $4.1 million to develop advanced cell based immune therapies for high-grade serous ovarian cancers that have become resistant to conventional treatments.
Tag: Natural Killer Cells
Short On Time? A 15-minute Workout May Help Boost Your Immune System
Exercising at moderate intensity for just 15 minutes may be all that is needed to boost immunity by increasing levels of natural killer (NK) cells. Researchers will present their work this week at the American Physiology Summit in Long Beach, California.
New Lung Immuno-oncology Therapeutic Strategy Identified
Researchers at the Icahn School of Medicine at Mount Sinai have demonstrated in a preclinical study a potential new therapeutic approach to treating the most common form of lung cancer. The strategy involves inhibiting the immune-system molecule TREM2 while enhancing natural killer cells (the so-called protectors of the immune system). It was described in the April 20 online issue of Nature Immunology.
An extra X chromosome-linked gene may explain decreased viral infection severity in females
Researchers may have found why viral infections hit males more severely than females. They found that female mouse and human NK cells have an extra copy of an X chromosome-linked gene called UTX. UTX acts as an epigenetic regulator to boost NK cell anti-viral function, while repressing NK cell numbers.
Tumor microbiome linked to immunotherapy success in sarcoma patients
A new UC Davis study reveals the interaction between tumor microbiome and the immune system may be the secret to improving outcomes for sarcoma patients.
Albert Einstein College of Medicine Researchers Develop Promising New Cancer Therapy
Immune checkpoint inhibitors such as Keytruda and Opdivo work by unleashing the immune system’s T cells to attack tumor cells. Their introduction a decade ago marked a major advance in cancer therapy, but only 10% to 30% of treated patients experience long-term improvement. In a paper published online today in The Journal of Clinical Investigation (JCI), scientists at Albert Einstein College of Medicine describe findings that could bolster the effectiveness of immune-checkpoint therapy.
Plant virus plus immune cell-activating antibody clear colon cancer in mice, prevent recurrence
A new combination therapy to combat cancer could one day consist of a plant virus and an antibody that activates the immune system’s “natural killer” cells, shows a study by researchers at the University of California San Diego. In mouse models of colon cancer, the combination therapy eliminated all tumors and prevented their recurrence, which in turn resulted in 100% survival. The therapy also increased survival in mouse models of melanoma.
Cell-based immunotherapy shows promise against melanoma
Researchers at Washington University School of Medicine in St. Louis have shown in preclinical studies conducted in mice and human cells that a type immunotherapy based on natural killer cells could be effective against solid tumors, starting with melanoma, a type of skin cancer that can be deadly if not caught early.
Scientists ‘Farm’ Natural Killer Cells in Novel Cancer Fighting Approach
Engineers and oncologists teamed to develop a microfluidic chip capable of capturing the body’s natural killer immune cells to harvest their cancer-killing exosomes.
2 immunotherapies merged into single, more effective treatment
Researchers at Washington University School of Medicine in St. Louis have combined two immunotherapy strategies into a single therapy and found, in studies in human cells and in mice, that the two together are more effective than either alone in treating certain blood cancers, such as leukemia.
Immunotherapy using ‘young cells’ offers promising option against cancer
A new study from Washington University School of Medicine in St. Louis suggests that the age of certain immune cells used in immunotherapy plays a role in how effective it is. These cells — natural killer (NK) cells — appear to be more effective the earlier they are in development, opening the door to the possibility of an immunotherapy that would not utilize cells from the patient or a matched donor. Instead, they could be developed from existing supplies of what are called human pluripotent stem cells.